These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 33823719)
1. Managing dyslipidemia in patients with Type 2 diabetes. Tomlinson B; Patil NG; Fok M; Lam CWK Expert Opin Pharmacother; 2021 Nov; 22(16):2221-2234. PubMed ID: 33823719 [TBL] [Abstract][Full Text] [Related]
2. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300 [TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia Management in Adults With Diabetes. Lazarte J; Hegele RA Can J Diabetes; 2020 Feb; 44(1):53-60. PubMed ID: 31521544 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms and Treatment of Dyslipidemia in Diabetes. Bahiru E; Hsiao R; Phillipson D; Watson KE Curr Cardiol Rep; 2021 Mar; 23(4):26. PubMed ID: 33655372 [TBL] [Abstract][Full Text] [Related]
5. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Lan NSR; Burns K; Bell DA; Watts GF Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):104-113. PubMed ID: 33278128 [TBL] [Abstract][Full Text] [Related]
6. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Yamashita S; Masuda D; Matsuzawa Y Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794 [TBL] [Abstract][Full Text] [Related]
7. Implications for REDUCE IT in clinical practice. Bittner V Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195 [TBL] [Abstract][Full Text] [Related]
8. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Duprez DA; Handelsman Y; Koren M Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551 [TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
11. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
12. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Chang Y; Eom S; Kim M; Song TJ Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734 [TBL] [Abstract][Full Text] [Related]
13. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Kim K; Ginsberg HN; Choi SH Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170 [TBL] [Abstract][Full Text] [Related]
14. Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. Warraich HJ; Rana JS Curr Cardiol Rep; 2018 Oct; 20(12):125. PubMed ID: 30311078 [TBL] [Abstract][Full Text] [Related]
18. Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. Ahmad MI; Shapiro MD Curr Atheroscler Rep; 2021 Mar; 23(4):16. PubMed ID: 33686460 [TBL] [Abstract][Full Text] [Related]
19. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192 [TBL] [Abstract][Full Text] [Related]
20. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]